Literature DB >> 15461591

The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells.

Valérie Fauquette1, Michael Perrais, Sylvain Cerulis, Nicolas Jonckheere, Marie-Paule Ducourouble, Jean-Pierre Aubert, Pascal Pigny, Isabelle Van Seuningen.   

Abstract

The human transmembrane mucin MUC4 is aberrantly expressed in 75% of pancreatic ductal adenocarcinomas, whereas no expression is found in normal pancreas. Therefore MUC4 appears as a useful biological marker for the diagnosis of ductal adenocarcinomas. Since rat Muc4 was shown to interact with ErbB-2 tyrosine kinase receptor and to either promote cell survival and differentiation or cell proliferation, it is postulated that MUC4 may also participate in pancreatic carcinogenesis. Our aim was to investigate in parallel the role of the Ets factor PEA3 in MUC4 and ErbB-2 transcriptional regulation in pancreatic cancer cells. Two MUC4-expressing WD (well-differentiated) (CAPAN-1 and -2) and one MUC4-non-expressing poorly differentiated (PANC-1) cell lines were used. The three cell lines express ErbB-2 at different levels. By co-transfection and site-directed mutagenesis, we show that PEA3 is a transactivator of the MUC4 promoter and that the -216 and -2368 PEA3 binding sites of the MUC4 promoter are essential. We also demonstrate that PEA3 acts in synergy with c-Jun and specificity protein 1 to transactivate the proximal region of the MUC4 promoter and increase MUC4 mRNA levels in WD cells. These results suggest that MUC4 is a new target gene of the Ets factor PEA3 in pancreatic cancer cells. In contrast, PEA3 represses the transcriptional activity of two fragments of the ErbB-2 promoter in a dose-dependent manner and decreases the endogenous ErbB-2 mRNA levels in WD cell lines. Thus, PEA3, by its capacity to up-regulate the epithelial marker MUC4 and to down-regulate the ErbB-2 oncogene, appears as a key regulator of the differentiation/proliferation balance in pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15461591      PMCID: PMC1134764          DOI: 10.1042/BJ20040706

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  Ets factors and regulation of the extracellular matrix.

Authors:  M Trojanowska
Journal:  Oncogene       Date:  2000-12-18       Impact factor: 9.867

3.  The PEA3 Ets transcription factor comprises multiple domains that regulate transactivation and DNA binding.

Authors:  B B Bojović; J A Hassell
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

4.  The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis.

Authors:  X Xing; S C Wang; W Xia; Y Zou; R Shao; K Y Kwong; Z Yu; S Zhang; S Miller; L Huang; M C Hung
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

5.  The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors.

Authors:  H C Crawford; B Fingleton; M D Gustavson; N Kurpios; R A Wagenaar; J A Hassell; L M Matrisian
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

6.  Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor.

Authors:  M Komatsu; S Jepson; M E Arango; C A Carothers Carraway; K L Carraway
Journal:  Oncogene       Date:  2001-01-25       Impact factor: 9.867

7.  ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor.

Authors:  J P Borg; S Marchetto; A Le Bivic; V Ollendorff; F Jaulin-Bastard; H Saito; E Fournier; J Adélaïde; B Margolis; D Birnbaum
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

8.  PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells.

Authors:  Z Su; Y Shi; R Friedman; L Qiao; R McKinstry; D Hinman; P Dent; P B Fisher
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

Review 9.  Molecular genetic basis of pancreatic adenocarcinoma.

Authors:  W Hilgers; S E Kern
Journal:  Genes Chromosomes Cancer       Date:  1999-09       Impact factor: 5.006

10.  Cloning and characterization of the 5' flanking region of the sialomucin complex/rat Muc4 gene: promoter activity in cultured cells.

Authors:  S A Price-Schiavi; A Perez; R Barco; K L Carraway
Journal:  Biochem J       Date:  2000-07-15       Impact factor: 3.857

View more
  8 in total

1.  Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer.

Authors:  J-S Zhang; A Koenig; A Harrison; A V Ugolkov; M E Fernandez-Zapico; F J Couch; D D Billadeau
Journal:  Oncogene       Date:  2011-03-28       Impact factor: 9.867

2.  Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha.

Authors:  Guillaume Piessen; Nicolas Jonckheere; Audrey Vincent; Brigitte Hémon; Marie-Paule Ducourouble; Marie-Christine Copin; Christophe Mariette; Isabelle Van Seuningen
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

Review 3.  Muc4/MUC4 functions and regulation in cancer.

Authors:  Kermit L Carraway; George Theodoropoulos; Goldi A Kozloski; Coralie A Carothers Carraway
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

4.  Transcriptional regulation of human MUC4 gene: identification of a novel inhibitory element and its nuclear binding protein.

Authors:  Jing-Jing Zhang; Yi Zhu; Xiong-Fei Zhang; Wen-Biao Liang; Kun-Ling Xie; Jin-Qiu Tao; Yun-Peng Peng; Ze-Kuan Xu; Yi Miao
Journal:  Mol Biol Rep       Date:  2013-06-30       Impact factor: 2.316

5.  Transcript profiling of Elf5+/- mammary glands during pregnancy identifies novel targets of Elf5.

Authors:  Renee L Rogers; Isabelle Van Seuningen; Jodee Gould; Paul J Hertzog; Matthew J Naylor; Melanie A Pritchard
Journal:  PLoS One       Date:  2010-10-07       Impact factor: 3.240

6.  A Double-Negative Feedback Interaction between miR-21 and PPAR-α in Clear Renal Cell Carcinoma.

Authors:  Marine Goujon; Justine Woszczyk; Kelly Gaudelot; Thomas Swierczewski; Sandy Fellah; Jean-Baptiste Gibier; Isabelle Van Seuningen; Romain Larrue; Christelle Cauffiez; Viviane Gnemmi; Sébastien Aubert; Nicolas Pottier; Michaël Perrais
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

7.  Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.

Authors:  N Jonckheere; V Fauquette; L Stechly; N Saint-Laurent; S Aubert; C Susini; G Huet; N Porchet; I Van Seuningen; P Pigny
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

8.  Mucins and pancreatic cancer.

Authors:  Nicolas Jonckheere; Nicolas Skrypek; Isabelle Van Seuningen
Journal:  Cancers (Basel)       Date:  2010-10-25       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.